On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...